AstraZeneca — Deal History & Benchmarks
Market Analysis
AstraZeneca has been involved in 20 transactions totaling $194.4B across Neurology & CNS, Immunology & Autoimmune, Oncology, Rare Disease, Hematology, Cardiovascular. As both a licensor and licensee, they have demonstrated a preference for licensing partnerships.
Key transactions include Alexion ($39B, 2021), Alexion Pharmaceuticals ($39B, 2021), Alexion/AstraZeneca ($7.5B, 2023).
Their deal activity is concentrated in Oncology (35%) with Small Molecule and Complement Inhibitor assets representing their most common deal types.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How many deals has AstraZeneca done?
What is AstraZeneca's typical deal structure?
What therapeutic areas does AstraZeneca focus on?
How has AstraZeneca's deal activity trended over time?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.